This discrepancy in outcomes to STING agonist therapies raises the possibility that targeting the STING pathway could be functionally relevant not only in antigen presenting cells of the host, which has been the focus of prior preclinical studies, but also in tumor cells with well documented epigenetically driven dysfunctional STING activity across several human cancer types, including melanoma29,35,43,44. The gene discussed is STING1; the disease is neoplasm.